In This Article:
Globus Medical GMED has experienced strong upward momentum in the past year, with its shares rising 41.8%. This has far outpaced the industry’s 7.5% decline and the S&P 500 composite’s 8.8% growth.
Currently carrying a Zacks Rank #3 (Hold), this renowned medical device company is gaining from the strong demand for its musculoskeletal solution products. The combined Globus Medical-NuVasive company is unlocking significant synergies, with more room to grow internationally. Moreover, the stock also benefits from a steady pace of new product introductions.
Headquartered in Audubon, PA, Globus Medical has an extensive portfolio comprising advanced and differentiated technologies that are used to treat a variety of musculoskeletal conditions of the spine, extremities and pelvis. The company currently has its sales operations distributed across 66 counties worldwide. Through the NuVasive Merger, it has expanded its global commercial reach, increased operational capabilities and further enhanced its comprehensive offerings of Musculoskeletal Solutions and Enabling Technologies.
Key Catalysts for GMED
The rally in the share price can be linked to the company gaining momentum in the musculoskeletal solutions market. In recent quarters, Globus Medical has outpaced the market growth in the U.S. spine business, fueled by combined product offerings, competitive rep recruiting from prior quarters and increased implant usage through robotic pull-through. In the fourth quarter of 2024, musculoskeletal sales improved 4.5% year over year, driven by strong gains in its international spine business and a 43.5% increase in global Enabling Technologies revenues.
Image Source: Zacks Investment Research
Furthermore, the company’s latest deal to acquire Nevro Corporation expands its footprint in the musculoskeletal space by an additional $2 billion. With its solid financial position, Globus Medical is well-positioned to accelerate investments in neuromodulation to expand both its current product lineup and future innovations. Moreover, the merger with NuVasive, completed in September 2023, has transformed the company into a global musculoskeletal powerhouse focused on rapid innovation, addressing unmet clinical needs, and improving offerings to surgeons and patients.
At the end of the fourth quarter, the combined company surpassed its 2024 synergy targets and was able to accelerate value creation and shareholder return as a result. For the second year’s synergies, the company is successfully implementing common systems in the international markets, expanding its in-house production for NuVasive implants, consolidating the external vendors and utilizing its existing product offerings to drive cross-selling. Even so, Globus Medical sees major untapped potential in its combined product offerings internationally, expecting it to be a significant tailwind in 2025 and beyond.